CN111217878B - Andrastone compounds, preparation method thereof and application thereof in preparing antiallergic drugs - Google Patents
Andrastone compounds, preparation method thereof and application thereof in preparing antiallergic drugs Download PDFInfo
- Publication number
- CN111217878B CN111217878B CN202010104064.1A CN202010104064A CN111217878B CN 111217878 B CN111217878 B CN 111217878B CN 202010104064 A CN202010104064 A CN 202010104064A CN 111217878 B CN111217878 B CN 111217878B
- Authority
- CN
- China
- Prior art keywords
- compound
- andrastone
- compounds
- preparation
- antiallergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
- C12P33/20—Preparation of steroids containing heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/80—Penicillium
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses andrastone compounds derived from deep-sea fungi, a preparation method thereof and application thereof in preparing antiallergic drugs. The structure of the andrastone compound 1-14 from the deep sea fungi is respectively shown as formulas I-XIV:
Description
Technical Field
The invention relates to the technical field of anti-allergic drugs, in particular to andrastone compounds, a preparation method thereof and application thereof in preparing anti-allergic drugs.
Background
Food allergy is a common allergic disease, which is caused by the cross-linking of allergen-specific IgE with fce R I, resulting in the release of allergic mediators from effector cells, and in severe cases, anaphylactic shock. Statistically, about 5% of adults and 8% of infants worldwide are allergic to food. Food allergy diseases cannot be completely cured at present, and the more common treatment method is drug control, such as antihistamines, hormones, receptor antagonists and the like. Although the medicine has quick response and obvious curative effect, the medicine has certain adverse reaction and is easy to generate drug resistance. In order to control the increase of allergic diseases, more researchers have developed novel natural active ingredients for preventing food allergic diseases in recent years.
The marine fungi live in special marine environments of high pressure, low temperature, oxygen deficiency and darkness, and often have special metabolic pathways in vivo so as to generate secondary metabolites with novel structures. Alkaloid compounds, terpenoid compounds, flavonoid compounds and the like from deep sea all show strong antiallergic activity. Therefore, the screening and discovery of natural products capable of targeting the antiallergic activity of nuclear receptors in marine fungi have important significance for the development of marine antiallergic drugs.
Disclosure of Invention
The invention aims to provide an andrastone compound, a preparation method thereof and application thereof in preparing an antiallergic medicament aiming at the defects in the prior art, and the andrastone compound can be used for treating diseases related to antiallergic.
The purpose of the invention is realized by the following technical scheme:
the andrastone compound has a structural formula shown as formulas I-XIV: .
The invention also provides a preparation method of the andrastone compound, which comprises the following steps:
s1, carrying out fermentation culture on Penicillium allii-sativi to obtain a fermentation product; the Penicillium Penicillium allii-sativi is preserved in China Marine microorganism culture preservation management center with the preservation number of MCCC 3A 00580;
s2, extracting the fermentation product, and separating and purifying the obtained extract to obtain the andrastone compound.
The invention also provides application of the andrastone compound or salts thereof in preparing antiallergic drugs.
The invention also provides an antiallergic drug, which comprises the andrastone compound and the salt thereof or the combination of more than two of the andrastone compound and the salt thereof which are used as active ingredients in effective dose, and a pharmaceutically acceptable carrier.
In particular, the salts include pharmaceutically acceptable salts.
The invention has the beneficial effects that:
the andrastone compound is obtained by separating from deep sea fungus Penicillium allii-sativi fermentation products, and is determined to be 14 compounds with the structures shown in formulas I-XIV through detailed structure analysis. According to the invention, researches show that the andrastone compound has strong efficiency of inhibiting the degranulation of rat basophilic granulocyte, so that a new compound source is provided for the research and development of allergic drugs, and the andrastone compound can be used for preparing the anti-allergic drugs and has a very good application prospect.
Detailed Description
In order to make the objects, technical solutions and technical effects of the present invention more clear, the present invention is described in detail below with reference to embodiments. It should be understood that the embodiments described in this specification are only for the purpose of illustrating the invention and are not to be construed as limiting the invention, and the parameters, proportions and the like of the embodiments may be suitably selected without materially affecting the results.
Example 1: preparation of andrastone compound
(1) Penicillium allii-sativi was cultured on PDA plates at 25 ℃ for 3 days. Fresh mycelium was then inoculated into culture medium containing 400mL of PDB. After 24 hours, 10mL of the seed solution was inoculated into a 1L Erlenmeyer flask (100 flasks) containing 80g of oat and 120mL of 3% seawater per flask and statically cultured at 28 ℃ for 30 days. Carrying out fermentation culture on the Penicillium allii-sativi to obtain a fermentation product;
the Penicillium allii-sativi is preserved in China marine microorganism strain preservation management center, and the preservation number is as follows: MCCC 3a 00580. See in particular the relevant literature "Andrastone A From the Deep-Sea-Deep FungiusPenicillium allii-sativi Acts as an indicator of Caspase and RXR-Dependent Apoptosis", Front. chem.2019, 7, 692, published in the Processes of Frontiers in Chemistry.
(2) Extracting the fermented product obtained in the step (1) with ethyl acetate for three times. The organic solvent was evaporated under reduced pressure to give an organic extract (200 g). The extracts were passed through a normal phase column chromatography using petroleum ether, dichloromethane and methanol for elution, respectively. The dichloromethane layer was concentrated to give a crude extract (63.0 g).
(3) Separating the crude extract obtained in the step (2) by using normal phase silica gel column chromatography, and performing gradient elution by using a petroleum ether-ethyl acetate system to obtain 8 crude fractions (Fr.1-Fr.8).
(4) The crude fraction Fr.3(6.3g) in step (3) was separated by ODS column chromatography, and gradient elution was carried out using a water-methanol system. Then, Sephadex LH-20 column chromatography was applied, and the resulting product was separated by elution with methanol and then recrystallized to give Compound 11(434.3 mg).
(5) The crude fraction Fr.4(2.1g) obtained in step (3) was passed through a Sephadex LH-20 gel column and eluted with methanol to give a subfraction Fr.4.1(1.2 g). Fr.4.1 was then subjected to ODS column Chromatography (CH)3OH-H2O, 60 → 100%) to yield 11 subfractions (Fr.4.1.1-Fr.4.1.11). Fr.4.1.2 by preparative HPLC column Chromatography (CH)3CN-H2O, 25 → 50%) to give compound 6(10.0 mg). The same preparative HPLC column chromatography was used to purify compound 2(2.5mg), compound 3(7.9mg), compound 9(3.4mg) and compound 12(39.0mg) from subfractions fr.4.1.8(50.9mg), fr.4.1.9(45.5mg) and fr.4.1.10(55.7mg), respectively.
(6) Subjecting the crude fraction Fr.5(3.5g) obtained in step (3) to ODS column Chromatography (CH)3OH-H2O, 60 → 100%) were separated into 11 sub-fractions. Fr.5.5 passing through Sephadex LH-20 (CH)3OH) column chromatography and preparative HPLC column Chromatography (CH)3-H2O, 50 → 100%) to give Compound 4(6.8mg), Compound 5(0.5mg), Compound7(27.1 mg). Fr.5.6 also by Sephadex LH-20 (CH)3OH) column chromatography and preparative HPLC column Chromatography (CH)3CN-H2O, 30 → 100%) to give compound 8(29.0mg), compound 10(9.1mg), and compound 13(9.6 mg). Fr.5.7 and Fr.5.8 were separately subjected to preparative HPLC column Chromatography (CH)3CN-H2O, 50 → 100%) to give Compound 1(5.3mg) and Compound 14(14.7 mg).
(7) Respectively analyzing and determining the plane structure of the compound 1-14 obtained in the step by using a 1D NMR spectrum, a 2D NMR spectrum and a high-resolution mass spectrum, and then determining the absolute configuration of the compound by using X-single crystal diffraction, ECD calculation and the like, wherein the detailed description is as follows:
compound 1 is a colorless orthorhombic crystal. Determining the molecular formula of the molecular formula C according to the main ion peak of the molecular formula in the high-resolution mass spectrum29H40O8。1H、13The C NMR data (tables 1, 2) and DEPT and HMBC spectra show 29 carbon signals, including 7 methyl groups, 2 methoxy groups, 3 methylene groups, 6 methine groups and 11 quaternary carbons, which are very close to dihydrocyclohybridonol, with only one more methyl group on the hydroxyl group at the C-23 position. The absolute configuration was determined by X-single crystal diffraction (Cu-Ka radiation) and was named citrhybridonol B.
The molecular formula of the compound 2 is C28H36O8，1H、13The C NMR data (tables 1, 2) shows 28 carbons, including 7 methyl groups, 1 methoxy group, 2 methylene groups, 7 methine groups, and 11 quaternary carbons. These signals are very close to andrastinA, except that compound 2 has a hydroxyl group at C-6, while a furan ring is formed between C-7 and C-15 via an oxygen bridge. Through detailed 1D and 2D NMR analyses and by combining a quantum chemical calculation method, the structure of the epioxandrastin A is finally determined to be 6 alpha-hydroxy-7 beta, 15-epoxynandrestatin A which is named as andrastin G.
The molecular formula of the compound 3 is C26H38O6Which is1H and13the C NMR spectrum was almost identical to that of andrastone A, except that there was one less acetyl group. Through detailed analysis of 1D and 2D NMR, the structure is determined to be 3-O-deacetylandrastone A which is named andrastone B.
The molecular formula of the compound 4 is C28H40O9. It is composed of1H and13the C NMR nuclear magnetic data are very close to that of the compound andrastone A, and the detailed analysis of COSY and HMBC maps confirms that the C-7 and C-23 positions of the compound 4 have two more hydroxyl groups (delta) than the andrastone AC 67.6d，δC62.3t), according to the very small coupling constant between H-5 and H-6: (3JH-5，H-62.4Hz), the 6-OH was determined to be in the alpha configuration, the calculated and experimental ECD spectra were further compared, and the absolute configuration of compound 4 was finally determined to be 6 alpha, 23-dihydroxyandrasoneA, named andrastone C.
The molecular formula of the compound 5 is C28H40O8. Analysis of1H、13C NMR nuclear magnetic data found very similar to compound 4, except that there was one less hydroxyl group at the C-6 position. In addition, the chemical shift values for C-16 and C-18 were significantly reduced by 3.6 and 5.5ppm, respectively, suggesting that their 16-OH should be in the alpha configuration rather than the beta configuration in Compound 4. In the NOESY map, H3-22 and H3-20/H2-23 is related, and H-9 is related to H3Correlation with-16 confirmed the alpha configuration of 16-OH. Thus, compound 5 was identified as 16-epi-23-hydroxydantrastone A, named andrastone D.
The molecular formula of the compound 6 is C28H38O8And (4) Na. It is composed of1H、13C NMR nuclear magnetic data are very similar to 5 except that compound 5 has a hydroxymethyl group at C-23 and an aldehyde group in compound 6. In HMBC mapping, H-23 correlates with C-1 and C-10 confirming the above inference. Thus, compound 6 was inferred to be 16-epi-23-oxoandrastone and named andrastone E.
The molecular formula of the compound 7 is C28H40O7. It is composed of1H、13The C NMR nuclear magnetic data was very similar to that of 5, except that there was one less hydroxyl group at the C-16 position than at 5, a conclusion that was confirmed by the correlation of COSY and HMBC. In the NOESY spectrum, H-16 is related to H-9, and H33' and H3-18/H3-20, thereby determining that the methyl group of C-18 is in the alpha configuration. As described above, the structure of Compound 7 was identified as 16-hydroxy-23-hydroxyandrastone a and named andrastone F.
The molecular formulas of the compounds 8 and 9 are respectively C26H38O7And C28H40O6. They showed a close resemblance to Compound 71H、13C NMR nuclear magnetic spectrum. The difference is determined by detailed COSY and HMBC spectrogram correlation analysis that the C-23 position in the compound 7 is hydroxymethyl, the compound 8 is aldehyde group, and the compound 9 is methyl. Further, NOESY confirmed that Compound 8 was 16-dehydroxy-23-oxoandrastone A (named andrastone G) and Compound 9 was 16-dehydroxyandtrastone A (named andrastone H). The other five known compounds 10-14 are identified by comparing the physical and chemical data of NMR nuclear magnetism, optical rotation, mass spectrum, etc. of the reference, respectively: 3-deacetylcitrohydrindiol (compound 10), citrohydrindiol (compound 11), citrohydrindione A (compound 12), 16-epi-citrohydrindione A (compound 13) and andrastin F (compound 14).
TABLE 2 preparation of compounds 1 to 913C NMR data (100MHz)
Determined using an HMBC map;aCD3OD；bCDCl3
example 2: EXAMPLE 1 examination of antiallergic Activity of Compounds 1 to 14 prepared in example 1
Rat Basophilic granulocytes (Rat Basophilic Leukemia-cell, RBL-cell) have good allergic immune response in the study of the diagnosis of food allergy and immunotherapy. The RBL-2H3 cell line has high activity and good homogeneity, and can be used for establishing an allergic reaction cell model. Therefore, the RBL-2H3 cell model is widely applied to the research of the anti-food allergy of natural active components, including degranulation, release of allergic medium and action mechanism thereof. And (3) detecting the degranulation efficiency of the cells after sensitization by using an immunoglobulin (IgE) mediated RBL-2H3 cell model, and calculating the inhibition rate of the compound sample on the degranulation efficiency of the cells so as to judge the anti-allergic activity of the sample.
The detailed steps are as follows:
1) pancreatin digestion to recover RBL-2H3 cells, 6X 105cells/mL, 100. mu.L per well (i.e., 6X 10)4cells/well) into 96-well plates, while adding anti-DNP-IgE to a final concentration of 1. mu.g/mL, incubator (37 ℃, 5% CO)2) Incubate overnight.
2) The wells were washed 3 times with PBS, the samples were dissolved in PBS, 5. mu.L of each sample was mixed with 95. mu.L of Tyyrode's buffer (final crude concentration 100. mu.g/mL, final monomer concentration 20. mu.g/mL), the negative control was 5. mu.L of PBS + 95. mu.L of Tyro de's buffer, 95. mu.L of each sample was added to the plates, and the incubation was continued for 1 h. RBL-2H3 cells were stimulated with 1. mu.g/mL DNP-BSA for 6 hours.
3) The activity of beta-hexosaminidase was detected using 4-methylumbellife-ryl-N-acetyl-b-Dglucosaminide substrate, and after recovering the cell culture supernatant, 100. mu.L of Tyrode's buffer (containing 0.1% Triton X-100) was added to the culture plate to lyse the cells; finally, 25 μ L of supernatant or cell lysate is respectively put into a 96-well fluorescent plate, 100 μ L of 4-methyl mbellife-ryl-N-acetyl-b-D-glucopyranosamide reagent (1.2mM) is added into each well, and the reaction is carried out for 30min (37 ℃), and the fluorescence value emitted by the solution at 450nm and excited at 360nm in each well is obtained by a microplate reader. Wherein loratadine is a positive control drug.
4) The particle removal efficiency calculation formula is as follows:
the degranulation efficiency was defined as the fluorescence value of the supernatant/(fluorescence value of the supernatant + fluorescence value of the cell lysate). times.100%
As can be seen from Table 3, compounds 3 and 10 have strong antiallergic activity and can significantly reduce the degranulation efficiency of RBL-2H3 cells, and the IC thereof50The values reached 40.4. mu.M and 14.8. mu.M, respectively, while the IC of the positive control drug loratadine50The concentration was 92.5. mu.M. The compound 14 has an inhibition rate of 35.6% on the cell degranulation efficiency of RBL-2H3, and other compounds show certain antiallergic activity to different degrees.
TABLE 3 antiallergic Activity of Compounds 1-14
NT, not tested
The result shows that the andrastone compound prepared by the invention has very good prospect of being developed into an antiallergic drug.
The above-mentioned embodiments are only for convenience of description, and are not intended to limit the present invention in any way, and those skilled in the art will understand that the technical features of the present invention can be modified or changed by other equivalent embodiments without departing from the scope of the present invention.
Claims (4)
1. An andrastone compound, which is characterized in that: the andrastone compound has a structural formula shown as formulas I-IX:
2. the process for preparing andrastone compounds as claimed in claim 1, characterized in that: the method comprises the following steps:
s1, carrying out fermentation culture on Penicillium allii-sativi to obtain a fermentation product; the Penicillium Penicillium allii-sativi is preserved in China Marine microorganism culture preservation management center with the preservation number of MCCC 3A 00580;
s2, extracting the fermentation product, and separating and purifying the obtained extract to obtain the andrastone compound.
3. The use of the andrastone compound or its salt according to claim 1 in the preparation of antiallergic drugs.
4. An antiallergic drug is characterized in that: the andrastone compound and the salt thereof which are used as active ingredients and are used as the active ingredients, and the pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010104064.1A CN111217878B (en) | 2020-02-21 | 2020-02-21 | Andrastone compounds, preparation method thereof and application thereof in preparing antiallergic drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010104064.1A CN111217878B (en) | 2020-02-21 | 2020-02-21 | Andrastone compounds, preparation method thereof and application thereof in preparing antiallergic drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111217878A CN111217878A (en) | 2020-06-02 |
| CN111217878B true CN111217878B (en) | 2021-06-15 |
Family
ID=70811710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010104064.1A Active CN111217878B (en) | 2020-02-21 | 2020-02-21 | Andrastone compounds, preparation method thereof and application thereof in preparing antiallergic drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111217878B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112047901B (en) * | 2020-09-21 | 2023-01-24 | 自然资源部第三海洋研究所 | Benzothiazole heteroterpenoid and derivative thereof, preparation method and application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109942658B (en) * | 2019-04-29 | 2020-08-14 | 自然资源部第三海洋研究所 | Heteroterpene compounds, preparation method and application thereof, and antitumor drugs |
-
2020
- 2020-02-21 CN CN202010104064.1A patent/CN111217878B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111217878A (en) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Isolation, structure elucidation, antioxidative and immunomodulatory properties of two novel dihydrocoumarins from Aloe vera | |
| CN111139188B (en) | Novel skeleton heteroterpene derivative derived from marine fungi and application of novel skeleton heteroterpene derivative in preparation of anti-inflammatory drugs | |
| CN112592350B (en) | Polyketide lithocarpin E-G and preparation method and application thereof | |
| CN109336873B (en) | Compound lithocarolsA-F, preparation method thereof and application thereof in preparation of antitumor drugs | |
| CN109232513B (en) | Compound litocarpinols, preparation method thereof and application thereof in preparation of antitumor drugs | |
| Li et al. | Anti-inflammatory fusicoccane-type diterpenoids from the phytopathogenic fungus Alternaria brassicicola | |
| Yang et al. | Abiespiroside A, an unprecedented sesquiterpenoid spirolactone with a 6/6/5 ring system from Abies delavayi | |
| Lin et al. | Collacyclumines A–D from the endophytic fungus Colletotrichum salsolae SCSIO 41021 isolated from the mangrove Kandelia candel | |
| Gao et al. | Trichothecenes from an endophytic fungus Alternaria sp. sb23 | |
| CN111217878B (en) | Andrastone compounds, preparation method thereof and application thereof in preparing antiallergic drugs | |
| CN113637010B (en) | Hydrogenated xanthone derivative and preparation method and application thereof | |
| Gao et al. | Cytochalasans from the endophytic fungus Diaporthe ueckerae associated with the fern Pteris vittata | |
| CN106967024A (en) | A kind of α pyrone derivatives and its preparation method and application | |
| Peng et al. | Structurally various sorbicillinoids from an endophytic fungus Acremonium citrinum SS-g13 | |
| CN109776561B (en) | Compounds Cytorhizins B and C, preparation method thereof and application thereof in preparation of antitumor drugs | |
| CN109942658B (en) | Heteroterpene compounds, preparation method and application thereof, and antitumor drugs | |
| CN111217706A (en) | Marine polyketide hypoxone A, preparation method thereof and application thereof in preparing anti-inflammatory drugs | |
| CN108558606B (en) | Sesterterpene compound peniroquesines, and preparation method and application thereof | |
| CN110330544A (en) | A kind of bicyclic steroid of 4,4,1- and its preparation method and application | |
| Gao et al. | Cytochalasan Alkaloids as TRAIL Sensitizers from an Endophytic Fungus Chaetomium sp. | |
| CN110498805B (en) | Bis-furoxanthone and bis-furoanthraquinone compounds, and preparation method and application thereof | |
| CN114989126A (en) | Azophilic ketone compound and preparation method and application thereof | |
| CN114933602A (en) | High-oxidation germacrane type sesquiterpene lactone compounds in elephantopus scaber and preparation method and application thereof | |
| CN100434419C (en) | Compound of monocyclic polysubstitution saturated cyclohexanones, prepartion method and usage | |
| CN113149820A (en) | Monocyclic heteroterpene structural compound, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |